Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery.
Abstract
BACKGROUND: Lung neuroendocrine neoplasms (LungNENs) comprise a heterogeneous group of tumors ranging from indolent lesions with good prognosis to highly aggressive cancers. Carcinoids are the rarest LungNENs, display low to intermediate malignancy and may be surgically managed, but show resistance to radiotherapy/chemotherapy in case of metastasis. Molecular profiling is providing new information to understand lung carcinoids, but its clinical value is still limited. Altered alternative splicing is emerging as a novel cancer hallmark unveiling a highly informative layer. METHODS: We primarily examined the status of the splicing machinery in lung carcinoids, by assessing the expression profile of the core spliceosome components and selected splicing factors in a cohort of 25 carcinoids using a microfluidic array. Results were validated in an external set of 51 samples. Dysregulation of splicing variants was further explored in silico in a separate set of 18 atypical carcinoids. Selected altered factors were tested by immunohistochemistry, their associations with clinical features were assessed and their putative functional roles were evaluated in vitro in two lung carcinoid-derived cell lines. RESULTS: The expression profile of the splicing machinery was profoundly dysregulated. Clustering and classification analyses highlighted five splicing factors: NOVA1, SRSF1, SRSF10, SRSF9 and PRPF8. Anatomopathological analysis showed protein differences in the presence of NOVA1, PRPF8 and SRSF10 in tumor versus non-tumor tissue. Expression levels of each of these factors were differentially related to distinct number and profiles of splicing events, and were associated to both common and disparate functional pathways. Accordingly, modulating the expression of NOVA1, PRPF8 and SRSF10 in vitro predictably influenced cell proliferation and colony formation, supporting their functional relevance and potential as actionable targets. CONCLUSIONS: These results provide primary evidence for dysregulation of the splicing machinery in lung carcinoids and suggest a plausible functional role and therapeutic targetability of NOVA1, PRPF8 and SRSF10.
Related
- Large-scale cerebrospinal fluid proteomics identifies diagnostic biomarker candidates across the clinico-pathological continuum of frontotemporal lobar degeneration
- ALSmiR: a curated evidence resource for ALS-associated microRNAs for biomarker discovery
- An alignment-last approach enables rapid transcriptomic biomarker discovery in large cohorts
- Discovery of novel enzybiotic candidates targeting human bacterial pathogens through large-scale viral-host profiling
- Integrating multi-omics with machine learning: from genomic variant functional annotation to pharmacogenomics and biomarker discovery
BibTeX
@article{blazquezencinas2026altered,
title = {{Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery.}},
author = {Ricardo Blázquez-Encinas and Víctor García-Vioque and Teresa Caro-Cuenca and María Trinidad Moreno-Montilla and Federica Mangili and Emilia Alors-Pérez and Sebastian Ventura and Aura D Herrera-Martínez and Paula Moreno-Casado and Marco A Calzado and Ángel Salvatierra and María A Gálvez-Moreno and Lynnette Fernandez-Cuesta and Matthieu Foll and Raúl M Luque and Nicolas Alcala and Sergio Pedraza-Arevalo and Alejandro Ibáñez-Costa and Justo P Castaño},
journal = {Journal of Translational Medicine},
year = {2026},
month = oct,
doi = {10.1186/s12967-023-04754-8},
url = {https://hal.science/hal-05842053v1},
note = {CC BY},
}
RIS
TY - JOUR
TI - Altered splicing machinery in lung carcinoids unveils NOVA1, PRPF8 and SRSF10 as novel candidates to understand tumor biology and expand biomarker discovery.
AU - Ricardo Blázquez-Encinas
AU - Víctor García-Vioque
AU - Teresa Caro-Cuenca
AU - María Trinidad Moreno-Montilla
AU - Federica Mangili
AU - Emilia Alors-Pérez
AU - Sebastian Ventura
AU - Aura D Herrera-Martínez
AU - Paula Moreno-Casado
AU - Marco A Calzado
AU - Ángel Salvatierra
AU - María A Gálvez-Moreno
AU - Lynnette Fernandez-Cuesta
AU - Matthieu Foll
AU - Raúl M Luque
AU - Nicolas Alcala
AU - Sergio Pedraza-Arevalo
AU - Alejandro Ibáñez-Costa
AU - Justo P Castaño
PY - 2026
DA - 2026/10/28
JO - Journal of Translational Medicine
DO - 10.1186/s12967-023-04754-8
UR - https://hal.science/hal-05842053v1
AB - BACKGROUND: Lung neuroendocrine neoplasms (LungNENs) comprise a heterogeneous group of tumors ranging from indolent lesions with good prognosis to highly aggressive cancers. Carcinoids are the rarest LungNENs, display low to intermediate malignancy and may be surgically managed, but show resistance to radiotherapy/chemotherapy in case of metastasis. Molecular profiling is providing new information to understand lung carcinoids, but its clinical value is still limited. Altered alternative splicing is emerging as a novel cancer hallmark unveiling a highly informative layer. METHODS: We primarily examined the status of the splicing machinery in lung carcinoids, by assessing the expression profile of the core spliceosome components and selected splicing factors in a cohort of 25 carcinoids using a microfluidic array. Results were validated in an external set of 51 samples. Dysregulation of splicing variants was further explored in silico in a separate set of 18 atypical carcinoids. Selected altered factors were tested by immunohistochemistry, their associations with clinical features were assessed and their putative functional roles were evaluated in vitro in two lung carcinoid-derived cell lines. RESULTS: The expression profile of the splicing machinery was profoundly dysregulated. Clustering and classification analyses highlighted five splicing factors: NOVA1, SRSF1, SRSF10, SRSF9 and PRPF8. Anatomopathological analysis showed protein differences in the presence of NOVA1, PRPF8 and SRSF10 in tumor versus non-tumor tissue. Expression levels of each of these factors were differentially related to distinct number and profiles of splicing events, and were associated to both common and disparate functional pathways. Accordingly, modulating the expression of NOVA1, PRPF8 and SRSF10 in vitro predictably influenced cell proliferation and colony formation, supporting their functional relevance and potential as actionable targets. CONCLUSIONS: These results provide primary evidence for dysregulation of the splicing machinery in lung carcinoids and suggest a plausible functional role and therapeutic targetability of NOVA1, PRPF8 and SRSF10.
SN - 1479-5876
ER -